S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Gas prices dip in NJ, around nation as cold weather returns
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Gas prices dip in NJ, around nation as cold weather returns
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Gas prices dip in NJ, around nation as cold weather returns
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Gas prices dip in NJ, around nation as cold weather returns
NASDAQ:ZLAB

Zai Lab - ZLAB Stock Forecast, Price & News

$40.09
-2.36 (-5.56%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$39.26
$41.97
50-Day Range
$28.97
$48.10
52-Week Range
$20.98
$61.29
Volume
595,839 shs
Average Volume
794,243 shs
Market Capitalization
$3.93 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$97.50

Zai Lab MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
143.2% Upside
$97.50 Price Target
Short Interest
Healthy
2.78% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.71mentions of Zai Lab in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$74,160 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.93) to ($4.11) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

369th out of 1,028 stocks

Pharmaceutical Preparations Industry

174th out of 501 stocks

ZLAB stock logo

About Zai Lab (NASDAQ:ZLAB) Stock

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.

Receive ZLAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter.

ZLAB Stock News Headlines

Zai Lab (NASDAQ:ZLAB) Trading Down 2.6%
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Zai Lab And Novocure Announce LUNAR Study Meets Primary Endpoint
NovoCure Gaps Sharply Higher for a Breakout: How to Play It
This Good News on Cancer Sent 2 Nasdaq Stocks Soaring
What's Going On With Zai Lab Stock
See More Headlines
Receive ZLAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter.

ZLAB Company Calendar

Last Earnings
11/09/2022
Today
2/05/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ZLAB
Employees
1,951
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$97.50
High Stock Price Forecast
$127.00
Low Stock Price Forecast
$79.00
Forecasted Upside/Downside
+143.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-704,470,000.00
Net Margins
-301.79%
Pretax Margin
-301.41%

Debt

Sales & Book Value

Annual Sales
$144.31 million
Book Value
$14.31 per share

Miscellaneous

Free Float
91,780,000
Market Cap
$3.93 billion
Optionable
Optionable
Beta
1.22

Key Executives

  • Ying DuYing Du
    Chairman & Chief Executive Officer
  • Rafael G. Amado
    President & Head-Global Oncology R&D
  • Joshua L. Smiley
    Chief Operating Officer
  • Billy Cho
    Chief Financial Officer
  • Ning Xu
    Executive VP & Head-Clinical Operations













ZLAB Stock - Frequently Asked Questions

Should I buy or sell Zai Lab stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZLAB shares.
View ZLAB analyst ratings
or view top-rated stocks.

What is Zai Lab's stock price forecast for 2023?

3 analysts have issued twelve-month price objectives for Zai Lab's stock. Their ZLAB share price forecasts range from $79.00 to $127.00. On average, they predict the company's stock price to reach $97.50 in the next year. This suggests a possible upside of 143.2% from the stock's current price.
View analysts price targets for ZLAB
or view top-rated stocks among Wall Street analysts.

How have ZLAB shares performed in 2023?

Zai Lab's stock was trading at $30.70 at the beginning of 2023. Since then, ZLAB stock has increased by 30.6% and is now trading at $40.09.
View the best growth stocks for 2023 here
.

When is Zai Lab's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our ZLAB earnings forecast
.

How were Zai Lab's earnings last quarter?

Zai Lab Limited (NASDAQ:ZLAB) released its quarterly earnings data on Wednesday, November, 9th. The company reported ($1.68) EPS for the quarter, missing analysts' consensus estimates of ($1.20) by $0.48. The business had revenue of $57.54 million for the quarter, compared to analyst estimates of $53.58 million. Zai Lab had a negative trailing twelve-month return on equity of 47.41% and a negative net margin of 301.79%.

What other stocks do shareholders of Zai Lab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).

When did Zai Lab IPO?

(ZLAB) raised $100 million in an initial public offering on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO.

What is Zai Lab's stock symbol?

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

Who are Zai Lab's major shareholders?

Zai Lab's stock is owned by many different institutional and retail investors. Top institutional investors include Segantii Capital Management Ltd (2.48%), Genesis Investment Management LLP (1.52%), M&G Investment Management Ltd. (0.47%), Sumitomo Mitsui Trust Holdings Inc. (0.21%), Zurcher Kantonalbank Zurich Cantonalbank (0.04%) and Bank of Montreal Can (0.04%). Insiders that own company stock include Harald Reinhart, John D Diekman, John D Diekman, Kai-Xian Chen, Peter Wirth, Tao Fu, William Ki Chul Cho, William Lis and Ying Du.
View institutional ownership trends
.

How do I buy shares of Zai Lab?

Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zai Lab's stock price today?

One share of ZLAB stock can currently be purchased for approximately $40.09.

How much money does Zai Lab make?

Zai Lab (NASDAQ:ZLAB) has a market capitalization of $3.93 billion and generates $196.61 million in revenue each year. The company earns $-704,470,000.00 in net income (profit) each year or ($6.22) on an earnings per share basis.

How many employees does Zai Lab have?

The company employs 1,951 workers across the globe.

How can I contact Zai Lab?

Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The official website for the company is www.zailaboratory.com. The company can be reached via phone at 862161632588, via email at jsteier@burnsmc.com, or via fax at 86-21-6163-2570.

This page (NASDAQ:ZLAB) was last updated on 2/5/2023 by MarketBeat.com Staff